The peroxisome proliferator-activated receptor (PPAR) β/δ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells
被引:92
作者:
Serrano-Marco, L.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Barcelona, Pharmacol Unit, Dept Pharmacol & Therapeut Chem, Fac Pharm,Inst Biomed UB IBUB, E-08028 Barcelona, Spain
Inst Salud Carlos III, CIBER Diabet & Enfermedades Metab Asociadas CIBER, Madrid, SpainUniv Barcelona, Pharmacol Unit, Dept Pharmacol & Therapeut Chem, Fac Pharm,Inst Biomed UB IBUB, E-08028 Barcelona, Spain
Serrano-Marco, L.
[1
,2
]
Barroso, E.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Barcelona, Pharmacol Unit, Dept Pharmacol & Therapeut Chem, Fac Pharm,Inst Biomed UB IBUB, E-08028 Barcelona, Spain
Inst Salud Carlos III, CIBER Diabet & Enfermedades Metab Asociadas CIBER, Madrid, SpainUniv Barcelona, Pharmacol Unit, Dept Pharmacol & Therapeut Chem, Fac Pharm,Inst Biomed UB IBUB, E-08028 Barcelona, Spain
Barroso, E.
[1
,2
]
El Kochairi, I.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Lausanne, Ctr Integrat Genom, Natl Res Ctr Frontiers Genet, Lausanne, SwitzerlandUniv Barcelona, Pharmacol Unit, Dept Pharmacol & Therapeut Chem, Fac Pharm,Inst Biomed UB IBUB, E-08028 Barcelona, Spain
El Kochairi, I.
[3
]
Palomer, X.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Barcelona, Pharmacol Unit, Dept Pharmacol & Therapeut Chem, Fac Pharm,Inst Biomed UB IBUB, E-08028 Barcelona, Spain
Inst Salud Carlos III, CIBER Diabet & Enfermedades Metab Asociadas CIBER, Madrid, SpainUniv Barcelona, Pharmacol Unit, Dept Pharmacol & Therapeut Chem, Fac Pharm,Inst Biomed UB IBUB, E-08028 Barcelona, Spain
Palomer, X.
[1
,2
]
论文数: 引用数:
h-index:
机构:
Michalik, L.
[3
]
论文数: 引用数:
h-index:
机构:
Wahli, W.
[3
]
论文数: 引用数:
h-index:
机构:
Vazquez-Carrera, M.
[1
,2
]
机构:
[1] Univ Barcelona, Pharmacol Unit, Dept Pharmacol & Therapeut Chem, Fac Pharm,Inst Biomed UB IBUB, E-08028 Barcelona, Spain
[2] Inst Salud Carlos III, CIBER Diabet & Enfermedades Metab Asociadas CIBER, Madrid, Spain
IL-6 induces insulin resistance by activating signal transducer and activator of transcription 3 (STAT3) and upregulating the transcription of its target gene SOCS3. Here we examined whether the peroxisome proliferator-activated receptor (PPAR)beta/delta agonist GW501516 prevented activation of the IL-6-STAT3-suppressor of cytokine signalling 3 (SOCS3) pathway and insulin resistance in human hepatic HepG2 cells. Studies were conducted with human HepG2 cells and livers from mice null for Ppar beta/delta (also known as Ppard) and wild-type mice. GW501516 prevented IL-6-dependent reduction in insulin-stimulated v-akt murine thymoma viral oncogene homologue 1 (AKT) phosphorylation and in IRS-1 and IRS-2 protein levels. In addition, treatment with this drug abolished IL-6-induced STAT3 phosphorylation of Tyr(705) and Ser(727) and prevented the increase in SOCS3 caused by this cytokine. Moreover, GW501516 prevented IL-6-dependent induction of extracellular-related kinase 1/2 (ERK1/2), a serine-threonine protein kinase involved in serine STAT3 phosphorylation; the livers of Ppar beta/delta-null mice showed increased Tyr(705)- and Ser(727)-STAT3 as well as phospho-ERK1/2 levels. Furthermore, drug treatment prevented the IL-6-dependent reduction in phosphorylated AMP-activated protein kinase (AMPK), a kinase reported to inhibit STAT3 phosphorylation on Tyr(705). In agreement with the recovery in phospho-AMPK levels observed following GW501516 treatment, this drug increased the AMP/ATP ratio and decreased the ATP/ADP ratio. Overall, our findings show that the PPAR beta/delta activator GW501516 prevents IL-6-induced STAT3 activation by inhibiting ERK1/2 phosphorylation and preventing the reduction in phospho-AMPK levels. These effects of GW501516 may contribute to the prevention of cytokine-induced insulin resistance in hepatic cells.